Dashboard
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.44 times
With a growth in Net Profit of 34.38%, the company declared Very Positive results in Sep 25
With ROCE of 8.6, it has a Attractive valuation with a 3.3 Enterprise value to Capital Employed
Market Beating Performance
Total Returns (Price + Dividend) 
Asarfi Hospital for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Asarfi Hospital Stock Hits New 52-Week High at Rs.221 Mark
Asarfi Hospital has reached a significant milestone by hitting a new 52-week high of Rs.221 today, marking a notable moment in the stock's recent performance and reflecting sustained momentum in the hospital sector.
Read More
Asarfi Hospital Stock Hits All-Time High, Marking a Significant Milestone
Asarfi Hospital has reached an all-time high, reflecting a remarkable phase in its market journey. The stock’s recent performance underscores its strong presence in the hospital sector, with notable gains and financial metrics that highlight its current standing.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
02-Dec-2025 | Source : BSEThis is to inform you that the Company will be meeting Investors/Analysts on dated November 04 2025 organized by Hem Securities - Samrudhi 2025 Virtual SME Conclave.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
27-Nov-2025 | Source : BSEWe wish to inform you that the management of the Company will be participating in Samruddhi2025(Season 2) - Nav Bharat ka Caravan Virtual Investor-Company Connect Conference organized by Hem Securities Limited which brings together some of Indias most emerging fast-growing and high-potential companies.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
22-Nov-2025 | Source : BSEWe hereby submit the transcript of the Earning Conference call held on November 19 2025 wherein the Unaudited Standalone & Consolidated financial Results for the half year ended September 30 2025 (FY26).
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.05%)
Harendra Singh (18.78%)
Gopal Singh (2.4%)
30.89%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 25.77% vs 5.22% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 34.37% vs -16.45% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Mar'25
Growth in half year ended Mar 2025 is 24.17% vs 22.01% in Sep 2024
Growth in half year ended Mar 2025 is 47.86% vs 107.01% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is 1.76% vs 6.00% in Sep 2025
YoY Growth in nine months ended Dec 2024 is 12.24% vs -33.58% in Sep 2025
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 42.86% vs 19.38% in Mar 2024
YoY Growth in year ended Mar 2025 is 160.81% vs -47.51% in Mar 2024







